Molecular and cellular insights into the pathogenesis of coronary artery ectasia

Öztürk, Serkan; Yetkın, Ertan; Waltenberger, Johannes

doi:10.1016/j.carpath.2018.04.005

Cited by 32 publications

(31 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased prevalence of CAE in recent years has resulted in a greater focus on the incidence and factors in uencing CAE [3];estimates of the incidence of coronary ectasia have varied from 0.3% to 4.7%. However, the etiopathogenetic mechanism of CAE is not yet completely known, although it may be related to systemic in ammation, stimulated nitric oxide production, coronary balloon angioplasty, nodular polyarteritis, and Kawasaki syndrome [4,5].…”

Section: Introductionmentioning

confidence: 99%

Anti-inflammatory effects of rosuvastatin treatment in coronary artery ectasia patients in different age groups

Fan

Hao

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Coronary artery ectasia (CAE) is an angiographic finding of abnormal coronary dilatation. The role of inflammation in atherosclerosis is becoming increasingly well known. This study investigated the relationship between CAE and serum levels of high-sensitivity C-reactive protein (Hs-CRP) and interleukin-6 (IL-6) to test our hypothesis that patient age is associated with the efficacy of anti-inflammatory therapy for CAE. Methods: We conducted a prospective analysis of 217 patients with CAE treated at the Department of Cardiology, Shanghai East Hospital, Shanghai East Hospital (Ji'an Campus), and Cardiovascular Medicine of Baoshan People’s Hospital of Yunnan Province, from January 1, 2015 to July 30, 2019. Baseline data of patients, including sex, age, hypertension, hyperlipidemia, and diabetes, were collected from patient medical records. Study participants were grouped by age as follows: CAE-A (age ≤50 years), CAE-B (50 years <age ≤70 years), and CAE-C (age >70). Additionally, there was a normal control (NC) group with normal coronary arteries.Results: All patients received oral rosuvastatin therapy (10 mg, QN quaque nocte) when they were diagnosed with CAE and maintained good follow-up, with a loss rate of 0.0% at the 6-month follow-up. The NC group (n = 73, with normal coronary arteries) received regular symptom-relieving treatments and rosuvastatin therapy. Among these four groups, the inflammatory markers were significantly higher in patients with CAE than in the NCs (p<0.01). Logistic regression analysis showed that Hs-CRP (OR=1.782, 95% CI: 1.124-2.014, P=0.021) and IL-6 (OR=1.584, 95% CI: 1.112-1.986, P=0.030) were independent predictors of CAE. The inflammatory markers in the CAE-A group were higher than those in the CAE-B group, which were higher than those in the CAE-C group. Follow-up after 6 months of rosuvastatin therapy showed a significantly greater reduction in Hs-CRP and IL-6 levels in the CAE-A group than in the CAE-B group, which, again, were higher than those in the CAE-C group. Conclusions: Anti-inflammatory therapy using rosuvastatin was more effective in younger CAE patients, indicating the need for early statin therapy in CAE patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Anti-inflammatory effects of rosuvastatin treatment in coronary artery ectasia patients in different age groups

Fan

Hao

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Frequent coexistence of CAE with CAD is the likely reason for the lack of knowledge regarding the exact mechanism of CAE. However, distinct differences between CAE and CAD have been documented in the literature in terms of clinical course and pathophysiologic steps and biomarkers [ 2 , 3 , 4 , 5 , 6 ]. The most promising difference is the increased inflammatory status in patients with CAE compared to those with normal coronary arteries and CAD, as demonstrated by Boles et al Increased cellular activation molecules such as intercellular adhesion molecule (ICAM), vascular cell adhesion molecule (VCAM), E-selectin, C-reactive protein, and activation markers of macrophages have already been documented as indicating increased inflammation in CAE compared to CAD [ 7 , 8 , 9 , 10 ].…”

mentioning

confidence: 99%

Inflammation in Coronary Artery Ectasia Compared to Atherosclerosis

Yetkın

Öztürk

Yetkin³

2018

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…On the other hand, the loss of musculoelastic arterial wall components in CAE was noticed to be unrelated to local atheromatous burden [ 38 , 39 ]. Although CAE has been known to be a variant of atherosclerosis in the literature, there are certain pathophysiologic mechanisms or clinical variables differentiating it from atherosclerosis [ 3 , 40 ]. Furthermore, CAE has been supposed to be a local manifestation of systemic vessel wall abnormality.…”

Section: Coronary Artery Ectasiamentioning

confidence: 99%

Dilating Vascular Diseases: Pathophysiology and Clinical Aspects

Yetkın

Öztürk²

2018

International Journal of Vascular Medicine

Self Cite

View full text Add to dashboard Cite

Atherosclerotic disease of the vessels is a significant problem affecting mortality and morbidity all over the world. However, dilatation of the vessels either in the arterial system or in the venous territory is another vessel disease. Varicocele, pelvic, and peripheral varicose veins and hemorrhoids are aneurysms of the venous vascular regions and have been defined as dilating venous disease, recently. Coronary artery ectasia, intracranial aneurysm, and abdominal aortic aneurysm are examples of arterial dilating vascular diseases. Mostly, they have been defined as variants of atherosclerosis. Although there are some similarities in terms of pathogenesis, they are distinct from atherosclerotic disease of the vessels. In addition, pathophysiological and histological similarities and clinical coexistence of these diseases have been demonstrated both in the arterial and in the venous system. This situation underlies the thought that dilatation of the vessels in any vascular territory should be considered as a systemic vessel wall disease rather than being a local disease of any vessel. These patients should be evaluated for other dilating vascular diseases in a systematic manner.

show abstract

Molecular and cellular insights into the pathogenesis of coronary artery ectasia

Cited by 32 publications

References 124 publications

Anti-inflammatory effects of rosuvastatin treatment in coronary artery ectasia patients in different age groups

Anti-inflammatory effects of rosuvastatin treatment in coronary artery ectasia patients in different age groups

Inflammation in Coronary Artery Ectasia Compared to Atherosclerosis

Dilating Vascular Diseases: Pathophysiology and Clinical Aspects

Contact Info

Product

Resources

About